News | February 23, 2024
Moderna posts Q4 2023 revenue at US$ 2.8 billion
Net product sales in the fourth quarter of 2023 include the recognition of $0.6 billion from deferred revenue, related to Gavi, the Vaccine Alliance
Net product sales in the fourth quarter of 2023 include the recognition of $0.6 billion from deferred revenue, related to Gavi, the Vaccine Alliance
IOL Chemicals and Pharmaceuticals’ product approved by CDE of NMPA, China
Through our research, we aim to ultimately provide new options for our customers to treat life-threatening infections in livestock
It is indicated for the inhibition of premature luteinizing hormone (LH) surges in women undergoing controlled ovarian hyperstimulation
Bromfenac Ophthalmic Solution 0.075% (RLD BromSite) had estimated annual sales of USD 15 million in the U.S.
Studies will Investigate Antidepressant Properties of Ketamir to Position for Initial IND Application in 2024
Developed by Pfizer, Abrocitinib has received marketing authorization from the Central Drugs Standard Control Organization (CDSCO) in India
Submission to be reviewed under FDA real-time oncology review and Project Orbis
This alliance brings together drug innovation capabilities of Glenmark and Ichnos to develop cutting-edge therapies for the treatment of hematological malignancies and solid tumors
Subscribe To Our Newsletter & Stay Updated
